Kind Pharmaceutical’s AND017 Gains the US FDA’s Orphan Drug Designation to Treat SCD
Shots:
- The US FDA has granted orphan drug designation to the company’s AND017 for the treatment of Sickle Cell Disease (SCD)
- P-I&II studies results for AND017 to treat anemia in NDD-CKD & DD-CKD are being presented at the ASN Kidney Week in San Diego. Non-clinical data supports AND017’s ODD for SCD will be presented in future scientific meetings and also be published in a scientific journal later on
- AND017 (HbEA) that works on multiple stages of the RBC life cycle. It is being developed to treat various types of anemia, including those associated with DD-CKD, NDD-CKD, CRA, MDS anemia, SCD, and β-thalassemia.
Ref: PR Newswire | Image: Kind Pharmaceuticals
Related News:- Iterum Therapeutics’ Orlynvah (Oral Sulopenem) Receives the US FDA’s Approval to Treat uUTIs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
